- Bacterial infections:
- Adults:
- Conventional interval dosing: IM/IV 7.5mg/kg/dose BD OR 5mg/kg/dose TDS
- Extended interval dosing: IM/IV 15-20mg/kg/dose OD
- Not indicated in pregnancy, burns, ascites, obesity, neutropenia or endocarditis
- Not indicated in pregnancy, burns, ascites, obesity, neutropenia or endocarditis
- Adults:
-
- Child ≥ 1 month:
- IV 5-7.5mg/kg/dose TDS
- IV 5-7.5mg/kg/dose TDS
- Child ≥ 1 month:
-
- <30 week gestation:
- 0-7 days: IV 18mg/kg/dose every 48h
- 8-28 days: IV 15mg/kg/dose every 36h
- ≥ 29 days: IV 15mg/kg/dose OD
- <30 week gestation:
-
- 30-34 week gestation:
- 0-7 days: IV 18mg/kg/dose every 36h
- ≥8 days: IV 15mg/kg/dose OD
- 30-34 week gestation:
-
- ≥35 week gestation
- 0-28 days: IV 15mg/kg/dose OD
- 0-28 days: IV 15mg/kg/dose OD
- ≥35 week gestation
- Hospital-acquired or ventilator-associated pneumonia:
- IV 15-20mg/kg/dose OD *1/52
- May administer with antipseudomonal beta-lactam or carbapenem
- Urinary tract infections (other than those caused by Pseudomonas):
- IV/IM 250mg BD
- A urinary alkalinising agent may be administered concurrently to increase pH and consequently enhance amikacin activity.
- Active TB (Off-label):
- IV/IM 10-15mg/kg/dose
- Not 1st-line agent
- Part of multi-drug regimen
- IV/IM 10-15mg/kg/dose
- IV/IM 250mg BD
- Bacterial endophthalmitis (Off-label):
- 4mg in 0.1mL sterile water or saline intravitreally *1
- Injection:
- 500mg/2mL
- 125mg/2mL
- Dilute 500mg to 100 or 200mL sterile diluent (0.9% NaCl or D5W)
- IM: Administer undiluted to upper outer quadrant of buttocks
- IV: Infuse over 30-60 min in adults and children; infuse over 1-2h in infants
- Do NOT mix with other medicines in a syringe or IV bag
Aminoglycoside
It irreversibly binds to 30S subunit of bacterial ribosomes inhibiting protein synthesis
- Elevated BUN or Cr
- Hearing loss
- Tinnitus
- Dizziness
- Vertigo
- Injection site reaction
- Neurotoxicity
- Nephrotoxicity
- Hypersensitivity to class/components
WARNING
- Increased risk of neurotoxicity, nephrotoxicity and ototoxicity
- Avoid concurrent or sequential use of neurotoxic and/or nephrotoxic drugs including other aminoglycosides (eg, amikacin, streptomycin, neomycin, kanamycin, gentamicin, paromomycin)
- Avoid potent diuretics (eg, ethacrynic acid, furosemide) because they increase risk of ototoxicity.
- Use with caution in premature infants and neonates because of renal immaturity and the resulting prolongation of serum half-life of the drug.
- Neuromuscular blockade including respiratory paralysis possible
- Amphotericin B
- Cidofovir
- Neomycin
Drug Status
Availability | Prescription only |
Pregnancy | Category D |
Breastfeeding | Not recommended |
Schedule | Not scheduled |
BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
---|---|---|---|---|---|
Amika 500 | 500mg/2mL | Injection | 1’s | Synermed Pharma | Synermed Pharma |
Amikanex | 500mg/2mL | Injection | 1’s | Umedica Labs | Unisel Ltd |
Amilab | 500mg/2mL | Injection | 1’s | Laborate India | Harley’s Ltd |
Mica | 500mg/2mL | Injection | 1’s | Brawn Labs | Sai Pharma |
Amikacin | 500mg/2mL | Injection | 1’s | Dawa Ltd | Dawa Ltd |
Lanomycin | 500mg/2mL | Injection | 1’s | Pharmathen Pharma | Goodman Agencies |
Lanomycin | 125mg/2mL | Injection | 1’s | Pharmathen Pharma | Goodman Agencies |